MARKETING & SALES STRATEGY:
The GHPC Marketing and Sales Campaigns will work in concert with sophisticated, intelligent public relations and corporate communications efforts.
This strategy will include regular attendance by senior GHPC members of the Scientific Board and marketing teams to major global, national and local medical meetings and conferences attended by healthcare professionals.
Of particular importance will be the international, national, state and local government healthcare administrators, doctors and medical professionals who attend to those afflicted with the target conditions.
Pharmaceutical Directors will be engaged who are responsible for the procurement of medications in public and private sector delivery systems, hospitals and clinics worldwide, and through that base, to the wider general practice healthcare marketplace. Most countries operate with a single government procurement system for all medical practitioners.
The US is different in allowing individual states, public and privately-owned hospitals, clinics and doctors to purchase or prescribe products through pharmacies (in the case of drugs) or directly from manufacturers or outlets (in the case of nutraceuticals).
GHPC will accelerate and expand the marketing process to take the message to a much wider audience among healthcare professionals, while at the same time, actively pursuing sales of ready-to-market products to significant bulk buyers.
Targeted marketing campaigns will further accelerate and amplify the enhanced nutrition message already stimulated and advanced by Dr. Dudrick. This will be implemented through various appropriate marketing forums, including global healthcare and nutraceutical-related events, symposiums and marketing fairs, learned societies, specific medical, marketing and nutritional forums, etc.
GHPC will pursue a dynamic, proactive sales and marketing campaign to launch the ready-to-market products.
Much initial use will be made of accessing existing marketing and distribution channels for all typical pharmaceutical and nutraceutical products. These comprise of major national distribution channels that supply large department store operations, chain pharmaceutical outlets, healthcare stores like GNC, clinics, hospitals, medical professionals, national drug and nutraceutical purchasing agencies and international medical funds in selected countries.
Initially, the effort will feature Myogence in various appropriate formulas that involve specific “before”, “during” and “after” exercise or work indication. The campaign will address the main vertical markets that have already been identified, including the geriatric community, anti-HIV/AIDS and other infectious disease patients, anti-obesity, general nutritional healthcare, amateur and professional sports nutrition, the US military services as well as NATO countries, firefighting services, ambulance and rescue services, and various other markets worldwide where test marketing and efficacy have already been completed.
The United States has its own unique system for distribution of healthcare-related products that GHPC will address via regional initiatives led by experienced marketing professionals, who have, or will establish, their own established customer relationships. Furthermore, there is a burgeoning market in “pet care” nutrients, supplements and energy products which merits future analysis.
INTERNATIONAL SALES & MARKETING:
As part of the international sales effort, GHPC has identified and will collaborate with existing appropriate national partners in target countries outside the USA to form strategic alliances amongst industry leaders with established distribution systems.
This includes Canada, Australia, New Zealand, all the members of the European Union (now 27 countries including Britain, France, Germany, Austria, Italy, Spain, Portugal, Greece, Poland, Hungary, Czech Republic, Belgium, Netherlands, Ireland, Sweden, Finland , and Denmark, etc), and others like Switzerland, Norway and Turkey that are not in the European Union, Eastern Europe (Russia and the CIS Countries) and the Balkan states (Serbia, Slovenia, Croatia, Bosnia and Herzegovina, Kosovo, Macedonia, and Montenegro), the African Union (57 countries), existing Middle Eastern distributors (especially in Gulf Co-operation Council countries ), Japanese, Chinese, Taiwanese, and Korean nutraceutical and pharmaceutical distribution channels.
GHPC has already made considerable progress meeting with their CEO’s, negotiating and establishing market contacts to begin selling directly into these well-established distribution systems worldwide. The primary geographical emphasis will initially be in North America and Europe, followed closely by penetration into the Third World.
PUBLIC RELATIONS & CORPORATE COMMUNICATIONS:
Effective Corporate Communications and Public Relations will be essential to GHPC success. Merrit Malloy will head up this division of the company. GHPC will leverage this advantage in obtaining greater public awareness of the benefits people can derive from these products, through intelligent liaison with several traditional media outlets. Dr. Dudrick and his Scientific Board colleagues have already published over 3,000 scientific and medical papers including articles and interviews in leading medical journals.
GHPC will continue to publish articles in the international media and medical press promoting its products. More editorials will be written, published and copied in all appropriate medical and broader media publications (such as the New England Journal of Medicine, Lancet Medical Bulletin, Medicine & Science in Sports and Exercise, World Health Organization Bulletins, the World Economic Forum, Presidential and International Healthcare Fora, National Institutes of Health, and various national Centers of Disease Control worldwide).
Ms. Malloy will author multiple media releases including a forthcoming book that will be a catalyst for illuminating the products. These activities will be accompanied by highly-organized public relations campaigns including appearances on many major television talk shows such as “Oprah”, “Charlie Rose”, “Ellen” DeGeneres, the “Larry King” Show, The “View”, the Early “Morning Shows” on network and local television; Health Programming television shows worldwide; TV and Cable television programs in the UK (BBC, ITV) and all the European, Asian and African Health programming channels (RTL, DTV, DW, SF DRS, OF, Euro Channel), etc.
Ms. Malloy provides GHPC with the distinct advantage of having personal, professional relationships with myriad producers, directors and presenters throughout the print, radio and television industry. In addition to targeted, label specific traditional marketing campaigns,
Ms. Malloy has demonstrated unique success in developing and launching public relations campaigns featuring individual meritorious medical professionals. GHPC will present Dr. Dudrick and the scientific team as candid, engaging and brimming with enthusiasm for these products and how they can change and improve lives.
They will be a formidable natural marketing force presented as “America’s Doctors” – extremely friendly, warm, caring and very real human beings. They represent the ideal human face of the archetypal family-oriented medical practitioner that has been lost in North America with the rush into, and dominance of, highly expensive, insurance-based medicine.
The GHPC PR Campaign will also address some of the concerns raised by the very real healthcare crisis in America that is predicated on spiraling costs, often unfriendly and unhelpful healthcare by medical professionals who do not always address the critical and underlying patient needs and requirements.
The extraordinary emphasis placed on healthcare in the recent US, Canadian, and several overseas national election campaigns, has proven that the issue has surged into the highest priority amongst most populations worldwide. It is one of the major underpinning costs impacting the economic meltdown and recession in global and national economies. Providing patients worldwide with low-cost, safe and efficacious products and services for treating the leading causes of disease-related death.
Existing & “Non-Traditional” Markets:
Lucrative markets exist worldwide within all of the armed forces, amateur and professional sports, and other specific target groups (police, fire, emergency and rescue services, etc.) requiring nutrition for endurance and longer term energy and performance enhancement. Positive results expected from new Clinical Trials will open additional non-traditional medical nutrition markets by developing new products to combat HIV/AIDS and other serious debilitating diseases worldwide, but especially in the African Sub-Sahara region. The primary geographical emphasis will initially be in North America and Europe, followed closely by penetration into Africa, Asia and the Pacific.
Since the early 1980’s, over 27 million people have died from HIV/AIDS and associated diseases (at the rate of 6,000 per day), while over 35 million patients remain infected and untreated. Myogence and its derivative products will restore the weakened immune systems and musculature of these patients with superior nutritional content to reinforce and support them during life-long anti-retroviral treatments.
Funds are immediately available to purchase GHPC products from PEPFAR (Washington DC) and GFATM (Geneva). More than $50 billion are now available over the next five years to expand ART programs already under way in recipient countries. This is a substantial multi-billion dollar market in its own right, which would represent an unique endorsement for GHPC to address many other targeted global health markets. 
.
